Table 5

Effect of CEBPA, FLT3, and BAALC status on clinical outcome

All (N = 67)CEBPA mutation (n = 12)CEBPA wild type (n = 55)PFLT3-ITD (n = 19)FLT3 wild type (n = 48)PBAALC high (n = 44)BAALC low (n = 23)P
CR1 achieved, %85100820.109384850.900682910.3008
Death in induction, %90110.23051080.2177990.9571
Death in CR1 (n)10101100
Relapse, %7025800.006084650.011577570.0289
OS median, mos (range, mos)13 (0-166)45.5 (20-166)12 (0-113)0.000710 (0-103)15.5 (0-166)0.014810 (0-103)21 (0-166)0.0210
DFS median, mos (range mos)10 (0-136)33.5 (9-136)10 (0-113)0.00178 (0-103)12.5 (0-136)0.03288.5 (0-136)21 (0-113)0.0152
DFS at three years, (n)115611065
OS at three years, (n)126611175
Patients disease-free in follow-up*, n
228144181111
Median, mos38602330433440
Range, mos4-13627-1364-1134-10310-13610-1364-113
  • NOTE. No patient died during consolidation therapy randomized to chemotherapy (n = 36) or to autologous transplantation (n = 10), and one patient died during allogeneic transplantation (1 of 11). DFS and OS are given as a median and also at the time point 3 years after diagnosis.

  • * Duration of follow-up is indicated for patients who are still disease-free with median value and range.